For years, psoriasis treatment has focused on calming the immune system at the level of the skin and joints. But dermatologists have increasingly emphasized that psoriasis is not just skin-deep. It is closely linked to systemic inflammation and metabolic health. New research suggests that treating both at the same time may lead to better outcomes.
In a 36-week phase 3b study sponsored by Eli Lilly, patients with moderate-to-severe plaque psoriasis who were also overweight or obese received the biologic Taltz either alone or in combination with the GLP-1 medication Zepbound. The combination performed significantly better. More than 27 percent of patients achieved complete skin clearance and lost at least 10 percent of their body weight, compared with 6 percent of patients treated with Taltz alone.
The study included 274 adults with an average body mass index above 39, a population that historically has shown lower response rates to biologic therapy.
“Psoriasis and obesity can profoundly impact how people feel, how they are seen, and how they live,” said Adrienne Brown, executive vice president and president, Lilly Immunology, in a press release. “For people living at the intersection of these chronic inflammatory diseases, these PASI 100 results represent far more than a clinical milestone. They demonstrate what becomes possible when we address both simultaneously.” Brown added that Taltz has a decade of proven efficacy in psoriasis, and that the improved outcomes seen when Zepbound was used alongside it may signal an important step forward for patients managing both conditions.
Nearly 61 percent of people in the U.S. living with psoriasis are also overweight or obese, and higher BMI has been associated with reduced treatment response. If approved and adopted more widely, the combination could reshape how dermatologists approach psoriasis treatment in patients with higher BMI. Rather than viewing each concern as a separate issue, the data point toward a more integrated strategy. For patients who have struggled to fully respond to biologics alone, addressing systemic inflammation and weight together may offer a meaningful new path forward.
